BMO Capital Markets set a $84.00 price target on AbbVie (NYSE:ABBV) in a research note released on Monday morning. The brokerage currently has a hold rating on the stock.

ABBV has been the topic of a number of other reports. UBS restated a neutral rating on shares of AbbVie in a research note on Friday, October 13th. Jefferies Group lifted their price objective on shares of AbbVie from $107.00 to $115.00 and gave the company a buy rating in a research note on Monday, October 16th. Cowen restated a hold rating and set a $95.00 price objective (up from $70.00) on shares of AbbVie in a research note on Monday, September 11th. Evercore ISI assumed coverage on shares of AbbVie in a research note on Wednesday, August 16th. They set an outperform rating and a $95.00 price objective on the stock. Finally, Piper Jaffray Companies lifted their price objective on shares of AbbVie to $115.00 and gave the company an overweight rating in a research note on Friday, October 27th. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $96.72.

Shares of AbbVie (NYSE ABBV) traded down $1.10 on Monday, hitting $95.22. 4,934,400 shares of the stock traded hands, compared to its average volume of 6,127,467. AbbVie has a 52 week low of $58.80 and a 52 week high of $98.52. The firm has a market capitalization of $152,460.00, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 1.36 and a beta of 1.53. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same period in the previous year, the business earned $1.21 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. equities analysts expect that AbbVie will post 5.55 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.98%. AbbVie’s payout ratio is 62.14%.

In other AbbVie news, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the sale, the vice president now directly owns 10,007 shares in the company, valued at $880,616. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last quarter, insiders sold 277,125 shares of company stock worth $25,891,756. 0.23% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Bristlecone Advisors LLC acquired a new stake in AbbVie during the 3rd quarter worth about $113,000. Acropolis Investment Management LLC acquired a new stake in AbbVie during the 2nd quarter worth about $106,000. Ffcm LLC raised its holdings in AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the period. Hudock Capital Group LLC raised its holdings in AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the period. Finally, Hershey Trust Co. acquired a new stake in AbbVie during the 3rd quarter worth about $139,000. Hedge funds and other institutional investors own 69.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AbbVie (ABBV) Given a $84.00 Price Target at BMO Capital Markets” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2017/12/05/abbvie-abbv-given-a-84-00-price-target-at-bmo-capital-markets.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.